Literature DB >> 19560743

Novel drug delivery strategies in neuro-oncology.

Dani S Bidros1, Michael A Vogelbaum.   

Abstract

Treatment of malignant gliomas represents one of the most formidable challenges in oncology. Despite treatment with surgery, radiation therapy, and chemotherapy, the prognosis remains poor, particularly for glioblastoma, which has a median survival of 12 to 15 months. An important impediment to finding effective treatments for malignant gliomas is the presence of the blood brain barrier, which serves to prevent delivery of potentially active therapeutic compounds. Multiple efforts are focused on developing strategies to effectively deliver active drugs to brain tumor cells. Blood brain barrier disruption and convection-enhanced delivery have emerged as leading investigational delivery techniques for the treatment of malignant brain tumors. Clinical trials using these methods have been completed, with mixed results, and several more are being initiated. In this review, we describe the clinically available methods used to circumvent the blood brain barrier and summarize the results to date of ongoing and completed clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19560743      PMCID: PMC5084189          DOI: 10.1016/j.nurt.2009.04.004

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  48 in total

1.  Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.

Authors:  Sandeep Kunwar; Susan M Chang; Michael D Prados; Mitchel S Berger; John H Sampson; David Croteau; Jeffrey W Sherman; Amy Y Grahn; Vince S Shu; Jeanne L Dul; Syed R Husain; Bharat H Joshi; Christoph Pedain; Raj K Puri
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

2.  Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Authors:  Ryuta Saito; Michal T Krauze; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; Mitchel S Berger; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

3.  Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

Authors:  L D McAllister; N D Doolittle; P E Guastadisegni; D F Kraemer; C A Lacy; J R Crossen; E A Neuwelt
Journal:  Neurosurgery       Date:  2000-01       Impact factor: 4.654

4.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

5.  Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier.

Authors:  S I Rapoport; P J Robinson
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

6.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

7.  Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study.

Authors:  P Menei; M C Venier; E Gamelin; J P Saint-André; G Hayek; E Jadaud; D Fournier; P Mercier; G Guy; J P Benoit
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

8.  Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival.

Authors:  D F Kraemer; D Fortin; N D Doolittle; E A Neuwelt
Journal:  Neurosurgery       Date:  2001-05       Impact factor: 4.654

9.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma.

Authors:  K A Walter; M A Cahan; A Gur; B Tyler; J Hilton; O M Colvin; P C Burger; A Domb; H Brem
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

Review 10.  Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.

Authors:  Michael Weaver; Douglas W Laske
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

View more
  39 in total

Review 1.  Intra-arterial chemotherapy for malignant gliomas: a critical analysis.

Authors:  J-K Burkhardt; H A Riina; B J Shin; J A Moliterno; C P Hofstetter; J A Boockvar
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

2.  Charting the course across the blood-brain barrier.

Authors:  David Nathanson; Paul S Mischel
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 3.  Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.

Authors:  Iason T Papademetriou; Tyrone Porter
Journal:  Ther Deliv       Date:  2015-08-25

4.  Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy.

Authors:  Hong Wu; Li Yao; Jiazhuan Mei; Feng Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

5.  Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma.

Authors:  Chuanyi Zheng; Chunyang Ma; Enqi Bai; Kun Yang; Ruxiang Xu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.

Authors:  Michael D Shultz; John D Wilson; Christine E Fuller; Jianyuan Zhang; Harry C Dorn; Panos P Fatouros
Journal:  Radiology       Date:  2011-08-03       Impact factor: 11.105

7.  Adenosine receptor signaling modulates permeability of the blood-brain barrier.

Authors:  Aaron J Carman; Jeffrey H Mills; Antje Krenz; Do-Geun Kim; Margaret S Bynoe
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

Review 8.  Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.

Authors:  Mikhail I Papisov; Vasily V Belov; Kimberley S Gannon
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

9.  Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.

Authors:  Xing-Qi Li; Zhi-Gang Ouyang; Sheng-Hua Zhang; Hong Liu; Yue Shang; Yi Li; Yong-Su Zhen
Journal:  J Neurooncol       Date:  2014-05-20       Impact factor: 4.130

10.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.